SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay-Reference-Cited by-同舟云学术

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay

Published:2021-07 Issue:7 Volume:27 Page:1029-1034
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Cassaniti Irene,Percivalle Elena,Bergami Federica,Piralla Antonio,Comolli Giuditta,Bruno Raffaele,Vecchia Marco,Sambo Margherita,Colaneri Marta,Zuccaro Valentina,Benazzo Marco,Robotti Carlo,Calastri Anna,Maiorano Eugenia,Ferrari Alessandro,Cambiè Giuseppe,Baldanti Fausto

Funder

European Commission

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference27 articles.

1. SARS-CoV-2 infection protects against rechallenge in rhesus macaques;Chandrashekar;Science,2020

2. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi red zone in Lombardy, Italy, as at 06 april 2020;Percivalle;Euro Surveill,2020

3. Antibody responses to SARS-CoV-2 in patients with COVID-19;Long;Nat Med,2020

4. Challenges of convalescent plasma therapy on COVID-19;Zhao;J Clin Virol,2020

5. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals;Zhang;J Med Virol,2006

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma Extracellular Vesicles Derived from Pediatric COVID-19 Patients Modulate Monocyte and T Cell Immune Responses Based on Disease Severity;Immunological Investigations;2024-08-08

2. Experimentally investigated “CoronaDerm-PS”-driven SARS-CoV-2-specific cellular immunity and safety;Russian Journal of Infection and Immunity;2024-08-05

3. Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses;Cell;2024-05

4. Identification and functional characteristic of SARS-CoV-2-specific T lymphocytes in COVID-19 patients up to 16 months after disease onset;Medical Immunology (Russia);2023-11-23

5. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab;Frontiers in Immunology;2023-09-20